I own alot of biotechs and they all have little red arrows...even TTPH which had good news..
just today's trading action based on some bad results/failed trials..
MRK reports tomorrow PreMarket.
In todays Sarasota Herald:
lzheimer's disease is the scourge of our aging populations. Soon, some 50 million people throughout the world will suffer from dementia, and the majority of them will have Alzheimer's Disease. For every affected person, there is an affected family. The societal and economic burdens imposed by this relentless, slow killer are the vexation of every developed economy.
Researchers now at the Roskamp Institute were members of a team that was the first in the world to show that, in certain rare cases, amyloid accumulation caused the disease. The question since then has been: Are all cases of Alzheimer's caused by am
Last week Biogen Idec, one of the larger pharmaceutical companies, announced encouraging news: The injection of aducanumab -- a drug consisting of an antibody directed toward a brain protein called amyloid -- has shown dramatic results in Alzheimer's patients.
Amyloid is produced throughout life by the brain but is normally degraded. However, when it accumulates, as in Alzheimer's Disease, it precedes -- and, many think, causes -- the destruction of brain cells.
From a patient and caregiver perspective, the most critical finding was that the antibody-treated patients suffered only minor decline in cognitive impairment over the year-long study period. The placebo-treated group experienced the usual, relentless decline in cognitive abilities (memory, language use, etc).
From a research perspective, the key finding was that the patients treated with the antibody showed reductions of amyloid in the brain; in contrast, the placebo-treated group accumulated more amyloid in their brains over the course of the study.
This critical finding revives a long-standing debate in the world of Alzheimer's research: Does accumulation of amyloid cause the disease or is it incidental?
The question is more than academic. If amyloid accumulation is only a consequence of the disease, then reducing it may be futile. If amyloid accumulation caus
Just received tha Annual Meeting info.
One of the items to vote on is a reverse split in the range of 1 for 5 to 1 for 25...as determined by the baord of Directors...
And so it begins to avoid delisting.....
MANATEE COUNTY - It was almost a year ago that the company now known as Rock Creek Pharmaceuticals was moved from Virginia to the Roskamp Institute campus here. At the same time, it changed from selling an over-the-counter neutraceutical that helped people quit smoking to a prescription pharmaceutical developer.
It has been a rough year, based on the company's annual report to the U.S. Securities and Exchange Commission and an interview with CEO Michael Mullan.
Last year, the company closed three offices: Washington D.C.; Glen Allen, Virginia; and Gloucester, Massachusetts. It also laid off two-thirds of its workers and incurred lawsuits.
The company reported a loss of $38.5 million for 2014, even more than the $32.8 million of 2013, when it was still known as Star Scientific.
As a marketing company, Star Scientific had cash flow from over-the-counter sales of two anatabine citrate-based products, trademarked as "Anatabloc" and "CigRx."
When the company began its transition, Rock Creek's team thought they could keep selling the over-the-counter neutraceutical while developing anatabine's résumé as a prescription product.
Change of plans
But the Food and Drug Administration thought otherwise. So in August, with an FDA action coming, Rock Creek voluntarily stopped selling Anatabloc and CigRx.
At roughly the same time, Mullan left his role as Roskamp's CEO in order to run Rock Creek.
"The downsizing is consistent with what the company is now," Mullan said. "It is a pharmaceutical-development company and is moving the compound through clinical trials. For that, you don't need a big staff."
The payroll, which was 28 going into the move, is now nine.
~ck (R/S. coming to stay listed)
And now the vulture lawyers are hovering over ACAD. big surprise.
Having seen the effects of Parkinson on patients and families, I hope there isn't more to this story as far as the delay.
CEO resigns the same day as the postponement seems strange. I'm not sure i am buying the "manufacturing" story.
I am looking for an entry point but will wait..not sure what will happen tomorrow morning.
~ck (Kerx looking safe right now)
In wake of the acquisition of of Cubist Pharmaceuticals, Watertown biotech firm Tetraphase Pharmaceuticals has become the area's leading developer of antibiotics, and now it's looking to double its cash on hand through a stock offering.
Tetraphase (Nasdaq: TTPH) shares were down about 4 percent as of 1:30 p.m. today after announcing plans to sell 3.4 million shares. At its current stock price of $34.60, that would raise $118 million on top of the $121 million in said it had as of Dec. 31 in its most recent financial update.
The company aims to submit its potential new antibiotic, called eravacycline, for approval in the U.S. later this year, pending the results of the second of two late-stage trials to be announcing in coming months. If approved, it would be the first for the biotech.
The company's success in bringing eravacycline to approval has resulted in speculation that it, too, could be acquired soon. Likely suitors have been named as Swiss drug giants Roche or Actelion Pharmaceuticals, New York-based Pfizer or New Jersey-based The Medicines Company. If it does eventually get purchased, it would be the second local antibiotics firm to be bought after Merck & Co. paid $9.5 billion for Cubist in a deal completed in January.
Here are the after hours trades: yes..it is there:
After Hours Time (ET) After Hours Price After Hours Share Volume
16:25 $ 23.38 Low 2,358
16:00 $ 23.7282 High 9,230
16:00 $ 23.7282 High 169
16:00 $ 23.38 100
16:00 $ 23.38 9,405
~ck (new investor in EXAS)
Keryx Biopharmaceuticals, Inc. has added a news release to its Investor Relations website.
Title: Keryx Biopharmaceuticals Announces Publication of Auryxia(TM) (ferric citrate) Analysis in Journal of the American Society of Nephrology
Date(s): 4-Mar-2015 7:45 AM
For a complete listing of our news releases, please click here
~ck (very long)
Sentiment: Strong Buy
I am still holding my shares even though they have tanked..
Anyone else here?
Sentiment: Strong Buy
Keryx Biopharmaceuticals, Inc. has posted a new presentation to its Investor Relations website.
Title: Cowen and Company 35th Annual Health Care Conference Presentation
Date(s): Mar 02 2015
I have been invested in KERX for a very long time and still own most of my position.
I was underwater for years when the stock was in the tank. I am sure many can remember.
I have been a subscriber to the WSJ for most of my adult life. I was not happy about the article, but to say it was a plant or they stooped too low is not a fair statement. The fact is, the launch has been disappointing as the PPS shows...and yes, it is early in the game.
I am hoping for the best over the longer term, but I have been to this rodeo before. Perhaps Ron and the BOD should have partnered or sold to a larger more established pharma. Time will tell.
I am not selling at this point.
Here are the trades in HART during the regular session on Friday:
This is a very thinly traded stock, so it doesn't take much to swing the pps.
You obviously know nothing about this company.
Construction is booming here in FL..In addition, many insurance companies are now requiring windows in existing homes to meet current hurricane code.
I bought more shares to average down today.
Although they are debt heavy, there is a good chaance for a rebound in oil later this year.
08:30 $ 12.29 200
08:24 $ 12.33 1,000
08:22 $ 12.35 High 5
08:22 $ 12.35 High 900
08:22 $ 12.25 5
08:22 $ 11.95 281
08:20 $ 12.07 5
08:20 $ 12.25 1,000
08:16 $ 11.94 Low 300
08:16 $ 11.94 Low 100
08:10 $ 11.96 100
08:06 $ 11.94 200